Search Result
Results for "
Calmodulin-dependent kinases
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W013857
-
|
CaMK
EGFR
Src
|
Cancer
|
Lavendustin C is a potent Ca 2+ calmodulin-dependent kinase II (CaMK II) inhibitor with an IC50 of 0.2 µM. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC50=0.012 µM) and pp60 c-src(+) kinase (IC50=0.5 µM) .
|
-
-
- HY-P1479A
-
|
Autophagy
CaMK
|
Neurological Disease
|
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
|
-
-
- HY-15465A
-
|
CaMK
Autophagy
|
Cancer
|
KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
|
-
-
- HY-15465
-
KN-93
Maximum Cited Publications
70 Publications Verification
|
CaMK
Autophagy
|
Cancer
|
KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
|
-
-
- HY-15465B
-
|
CaMK
Autophagy
|
Cancer
|
KN-93 phosphate is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM .
|
-
-
- HY-W170020
-
|
CaMK
|
Metabolic Disease
|
PTCA is a potent Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) ligand with a pKi value of 7.2 .
|
-
-
- HY-P3811A
-
|
CaMK
|
Neurological Disease
|
Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca 2+/calmodulin-dependent kinase II) (CaMK) substrate .
|
-
-
- HY-P1479
-
|
Autophagy
CaMK
|
Neurological Disease
|
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
|
-
-
- HY-P1874
-
|
Calmodulin
|
Neurological Disease
|
Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .
|
-
-
- HY-P10499
-
|
CaMK
|
Others
|
[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors .
|
-
-
- HY-P3811
-
|
CaMK
|
Neurological Disease
|
Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca 2+/calmodulin-dependent kinase II) (CaMK) substrate .
|
-
-
- HY-100779
-
SMP 114
|
CaMK
Autophagy
|
Metabolic Disease
|
Rimacalib (SMP 114) is a Ca 2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ .
|
-
-
- HY-19805A
-
|
CaMK
AMPK
Autophagy
|
Metabolic Disease
|
STO-609 acetate is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
|
-
-
- HY-19805
-
|
CaMK
AMPK
Autophagy
|
Metabolic Disease
|
STO-609 is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
|
-
-
- HY-146268
-
|
CaMK
|
Neurological Disease
|
CaMKIIα-IN-1 (Compound 4d) is an orally active Ca 2+/calmodulin-dependent protein kinase II α (CaMKIIα) inhibitor with a KD of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability .
|
-
-
- HY-P3944
-
|
CaMK
|
Neurological Disease
|
Calmodulin Dependent Protein Kinase Substrate is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .
|
-
-
- HY-P3943
-
|
CaMK
|
Neurological Disease
|
Calmodulin Dependent Protein Kinase Substrate Analog is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .
|
-
-
- HY-111093
-
|
CaMK
|
Neurological Disease
|
Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .
|
-
-
- HY-N6732
-
SF2370; Antibiotic K 252a; Antibiotic SF 2370
|
PKC
PKA
CaMK
Trk Receptor
Autophagy
Antibiotic
|
Infection
Inflammation/Immunology
|
K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca 2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .
|
-
-
- HY-P1821A
-
MHP4-14 TFA
|
PKC
|
Neurological Disease
|
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
-
- HY-P1821
-
MHP4-14
|
PKC
|
Neurological Disease
|
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
-
- HY-110140
-
|
CaMK
|
Cardiovascular Disease
Neurological Disease
|
(E)-KN-93 phosphate is an inhibitor for Ca 2+/calmodulin-dependent protein kinase II (CaMK II) with IC50 of 9 μM and 3 μM, for CaMKIIδ monomer and CaMKIIδ dodecamer. (E)-KN-93 phosphate binds competitively with Ca 2+/CaM, and disrupts their interaction with CaMK II, and thus inhibits the CaMK II activation .
|
-
-
- HY-13290
-
|
CaMK
P2X Receptor
|
Metabolic Disease
Cancer
|
KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a Ki of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
|
-
-
- HY-137658A
-
PTP tetrasodium
|
Nucleoside Antimetabolite/Analog
DNA/RNA Synthesis
CaMK
|
Metabolic Disease
|
Purine riboside-5'-O-triphosphate sodium, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM .
|
-
-
- HY-137658
-
PTP
|
Nucleoside Antimetabolite/Analog
DNA/RNA Synthesis
CaMK
|
Metabolic Disease
|
Purine riboside-5'-O-triphosphate, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate also inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM .
|
-
-
- HY-P5525
-
Autocamtide-3 Derived Inhibitory Peptide
|
CaMK
|
Others
|
AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)
|
-
-
- HY-Z0478
-
(S)-(-)-Limonene
|
Bacterial
Antibiotic
CaMK
|
Infection
Cardiovascular Disease
Metabolic Disease
|
(-)-Limonene ((S)-(-)-Limonene) is orally active and can cause mild bronchoconstriction. (-)-Limonene alleviates cytosolic and mitochondrial oxidative stress by inhibiting the increase of calcium ions (Ca 2+) and Ca 2+/calmodulin-dependent protein kinase II (CaMKII). It also exerts anti-stress effects by inhibiting the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, (-)-Limonene can be used as an antibacterial agent in aquaculture .
|
-
-
- HY-130368
-
-
-
- HY-108599
-
DCP-LA
5 Publications Verification
FR236924
|
PKC
CaMK
Phosphatase
Apoptosis
|
Neurological Disease
|
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( 2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .
|
-
-
- HY-100912
-
|
Phosphodiesterase (PDE)
Myosin
Apoptosis
Calmodulin
Potassium Channel
|
Cancer
|
W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .
|
-
-
- HY-P0225
-
Autocamtide II
|
CaMK
Autophagy
|
Neurological Disease
|
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.
|
-
-
- HY-108599R
-
FR236924 (Standard)
|
Reference Standards
PKC
CaMK
Phosphatase
Apoptosis
|
Neurological Disease
|
DCP-LA (Standard) is the analytical standard of DCP-LA. This product is intended for research and analytical applications. DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].
|
-
-
- HY-P10638
-
|
CaMK
|
Neurological Disease
|
TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII), a ubiquitously-expressed multifunctional serine/threonine protein kinase, with an IC50 of 77 nM. TatCN21 can be utilized in research on ischemia and neurodegenerative diseases .
|
-
-
- HY-148907
-
|
CaMK
MEK
Mixed Lineage Kinase
|
Cancer
|
CS640 is a selective inhibitor of calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC50 values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC50 values of 6 and 10 μM, respectively .
|
-
-
- HY-156104
-
|
PROTACs
CaMK
|
Neurological Disease
|
CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .
|
-
-
- HY-P1716
-
|
PKC
|
Neurological Disease
|
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .
|
-
-
- HY-168905
-
|
Calmodulin
|
Cancer
|
SGC-CAMKK2-1 is the selective, inhibitor for calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) with an IC50 of 30 nM. SGC-CAMKK2-1 inhibits AMPK phosphorylation in cell C4-2 with an IC50 of 1.6 µM .
|
-
-
- HY-116153
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
HUHS2002 is a free fatty acid derivative with the ability to enhance α7 cholinergic receptor activity. HUHS2002 enhances whole-cell membrane currents of α7 ACh receptors expressed in Xenopus oocytes in a concentration-dependent manner. The effects of HUHS2002 were blocked in the presence of the Ca2 /calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93. HUHS2002 activated CaMKII in cultured rodent hippocampal neurons, and this activation was abolished by KN-93. HUHS2002 also partially inhibited the activity of protein phosphatase 1 (PP1) in a cell-free PP1 activity assay .
|
-
-
- HY-P10367
-
|
MAPKAPK2 (MK2)
Checkpoint Kinase (Chk)
AMPK
|
Others
|
Ziptide is a substrate for MAPK activated protein kinase 2 (MAPKAPK2, Km = 5 μM), MAPKAPK3 (Km = 30 μM), PARK (Km = 40 μM), checkpoint kinase 1 (Chk1, Km = 5 μM), AMP-activated protein kinase (AMPK, Km = 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, Km = 300 μM) .
|
-
-
- HY-P10638A
-
|
CaMK
|
Neurological Disease
|
TAT-CN21 (scrambled) is a control peptide lacking specific targeting activity, used as a negative control for TatCN21 (HY-P10638). TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII) .
|
-
-
- HY-P10316
-
Calmodulin-dependent Protein Kinase I (299-320) Binding Domain
|
CaMK
|
Others
|
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1479A
-
|
Autophagy
CaMK
|
Neurological Disease
|
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
|
-
- HY-P3811A
-
|
CaMK
|
Neurological Disease
|
Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca 2+/calmodulin-dependent kinase II) (CaMK) substrate .
|
-
- HY-P1821A
-
MHP4-14 TFA
|
PKC
|
Neurological Disease
|
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
- HY-P1821
-
MHP4-14
|
PKC
|
Neurological Disease
|
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
- HY-P1479
-
|
Autophagy
CaMK
|
Neurological Disease
|
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
|
-
- HY-P1874
-
|
Calmodulin
|
Neurological Disease
|
Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .
|
-
- HY-P10499
-
|
CaMK
|
Others
|
[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors .
|
-
- HY-P3811
-
|
CaMK
|
Neurological Disease
|
Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca 2+/calmodulin-dependent kinase II) (CaMK) substrate .
|
-
- HY-P3944
-
|
CaMK
|
Neurological Disease
|
Calmodulin Dependent Protein Kinase Substrate is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .
|
-
- HY-P3943
-
|
CaMK
|
Neurological Disease
|
Calmodulin Dependent Protein Kinase Substrate Analog is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .
|
-
- HY-P5525
-
Autocamtide-3 Derived Inhibitory Peptide
|
CaMK
|
Others
|
AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)
|
-
- HY-P0225
-
Autocamtide II
|
CaMK
Autophagy
|
Neurological Disease
|
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.
|
-
- HY-P10638
-
|
CaMK
|
Neurological Disease
|
TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII), a ubiquitously-expressed multifunctional serine/threonine protein kinase, with an IC50 of 77 nM. TatCN21 can be utilized in research on ischemia and neurodegenerative diseases .
|
-
- HY-P1716
-
|
PKC
|
Neurological Disease
|
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .
|
-
- HY-P10367
-
|
MAPKAPK2 (MK2)
Checkpoint Kinase (Chk)
AMPK
|
Others
|
Ziptide is a substrate for MAPK activated protein kinase 2 (MAPKAPK2, Km = 5 μM), MAPKAPK3 (Km = 30 μM), PARK (Km = 40 μM), checkpoint kinase 1 (Chk1, Km = 5 μM), AMP-activated protein kinase (AMPK, Km = 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, Km = 300 μM) .
|
-
- HY-P10638A
-
|
CaMK
|
Neurological Disease
|
TAT-CN21 (scrambled) is a control peptide lacking specific targeting activity, used as a negative control for TatCN21 (HY-P10638). TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII) .
|
-
- HY-P10316
-
Calmodulin-dependent Protein Kinase I (299-320) Binding Domain
|
CaMK
|
Others
|
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N6732
-
SF2370; Antibiotic K 252a; Antibiotic SF 2370
|
Alkaloids
Structural Classification
Microorganisms
Classification of Application Fields
Source classification
Inflammation/Immunology
Disease Research Fields
Indole Alkaloids
|
PKC
PKA
CaMK
Trk Receptor
Autophagy
Antibiotic
|
K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca 2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .
|
-
-
- HY-Z0478
-
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: